A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)

Degirmencioglu, Serkan; Tanriverdi, Ozgur; Menekse, Serkan; Dogan, Mutlu; Hacioglu, Bekir; Oktay, Esin; Erdem, Dilek; Arpaci, Erkan; Uluc, Basak; Turhal, Serdar; Yilmaz, Merve; Pilanci, Kezban; Sakin, Abdullah; Araz, Murat; Cokmert, Suna; Ozdemir, Ozlem; Sen, Erdem; Nayir, Erdinc

A retrospective analysis on first-line bevacizumab, cetuximab, and panitumumab-containing regimens in patients with RAS-wild metastatic colorectal cancer: A Collaborative Study by Turkish Oncology Group (TOG)

Degirmencioglu S., Tanriverdi O., Menekse S., Dogan M., Hacioglu B., Oktay E., ...Daha Fazla

JOURNAL OF BUON, cilt.24, sa.1, ss.242-248, 2019 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 24 Sayı: 1
Basım Tarihi: 2019
Dergi Adı: JOURNAL OF BUON
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.242-248
Van Yüzüncü Yıl Üniversitesi Adresli: Evet

Özet

Purpose: To compare the efficacy and adverse effect profiles of the first-line treatment of patients with KRAS wild type metastatic colorectal cancer (CRC) in Turkey who were treated based on regimens including bevacizumab, cetuximab and panitumumab.